Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel
The ARV Guidelines Panel issued a strong recommendation for initiating statin therapy among PWH with a 10-year ASCVD risk score of 5% or higher, whose absolute benefit from statins in REPRIEVE was greatest. For patients with a 10-year ASCVD risk score below 5%, the Panel favored statins but recommended patient-clinician risk discussions considering additional HIV-related factors that can increase ASCVD risk.
Authors
- Grace A. McComsey (ORCID: https://orcid.org/0000-0003-2690-8888)
- Salim S. Virani (ORCID: https://orcid.org/0000-0001-9541-6954)
- Seth S. Martin (ORCID: https://orcid.org/0000-0002-7021-7622)
- David V. Glidden (ORCID: https://orcid.org/0000-0001-5888-1419)
- Craig James Beavers (ORCID: https://orcid.org/0000-0002-2990-3989)
- Jason V. Baker (ORCID: https://orcid.org/0000-0002-5542-1545)
- Safia Kuriakose (ORCID: https://orcid.org/0009-0001-4076-6276)
- Emily P. Hyle (ORCID: https://orcid.org/0000-0001-8721-106X)
- Alice K. Pau (ORCID: https://orcid.org/0000-0002-0153-0236)
- Melanie Thompson (ORCID: https://orcid.org/0009-0005-0341-2400)
Institutions
- Aga Khan University (PK)
- National Institutes of Health (US)
- University of Minnesota (US)
- University of Kentucky (US)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Johns Hopkins Medicine (US)
- University of Minnesota System (US)
- Massachusetts General Hospital (US)
- Frederick National Laboratory for Cancer Research (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Annals of Internal Medicine
- Published
- 2025-05-26
- DOI
- https://doi.org/10.7326/annals-24-03564
- Citations
- 12
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 27.04